Table 4.
Perioperative outcomes stratified by receipt of extended-duration low molecular weight heparin prophylaxis.
| Colectomy | Oophorectomy | Hysterectomy | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Events5 | (%) | Odds Ratio (95% CI) | Events5 | (%) | Odds Ratio (95% CI) | Events5 | (%) | Odds Ratio (95% CI) | |
| VTE 1 | |||||||||
| Extended-Duration LMWH | |||||||||
| No | 1,146 | (2.9) | Referent | 329 | (3.6) | Referent | 283 | (2.1) | Referent |
| Yes | 20 | (2.4) | 0.84 (0.54–1.31) | 62 | (3.7) | 1.01 (0.76–1.33) | 33 | (2.1) | 0.96 (0.67–1.38) |
| Transfusion 2 | |||||||||
| Extended-Duration LMWH | |||||||||
| No | 379 | (1.0) | Referent | 166 | (2.0) | Referent | 98 | (0.8) | Referent |
| Yes | 17 | (2.2) | 2.18 (1.34–3.56)* | 31 | (2.0) | 1.00 (0.68–1.47) | 11 | (0.7) | 0.90 (0.48–1.70) |
| Hemorrhage 3 | |||||||||
| Extended-Duration LMWH | |||||||||
| No | 367 | (1.0) | Referent | 87 | (1.0) | Referent | 149 | (1.2) | Referent |
| Yes | 13 | (1.6) | 1.70 (0.97–2.97) | 26 | (1.6) | 1.59 (1.02–2.46)* | 19 | (1.2) | 1.05 (0.65–1.69) |
| Composite (transfusion, hemorrhage) 4 | |||||||||
| Extended-Duration LMWH | |||||||||
| No | 664 | (1.8) | Referent | 233 | (2.8) | Referent | 224 | (1.8) | Referent |
| Yes | 30 | (3.9) | 2.20 (1.51–3.19)* | 55 | (3.4) | 1.24 (0.92–1.68) | 27 | (1.8) | 0.99 (0.66–1.48) |
p-value < 0.05. LMWH post hospital is defined as daily dose of enoxaparin ≤ 40 mg and/or dalteparin ≤ 5000 IU within 1 week after hospitalization (starting from date of discharge), and no VTE diagnosis before LMWH. 171, 147, and 166 patients who received therapeutic LMWH (Lovenox > 40 mg and/or Fragmin > 5000 IU) and/or who had diagnosis of VTE before LMWH were grouped as no for LMWH post hospital in the colectomy, oophorectomy, and hysterectomy cohort and included in deriving the propensity score. Age, sex, year, region, comorbidity, hysterectomy, oophorectomy, colectomy, and hospital complications (any of transfusion or hemorrhage) and all possible two-way interactions were included in the models for propensity score.
Number of patients in the pseudocohort after applying IPTW is 40,258, 10,765, and 14,848 for colon, ovarian, and uterine cohort.
171, 147, and 166 patients who received therapeutic LMWH (enoxaparin > 40 mg and/or dalteparin > 5000 IU) and/or who had diagnosis of VTE before LMWH, and 2,245, 496, and 334 patients who had transfusion in hospital were excluded from the colectomy, oophorectomy, and hysterectomy cohort. Number of patients after applying IPTW is 37,838, 10,083, and 14,334 for the colectomy, oophorectomy, and hysterectomy cohortrespectively.
171, 147, and 166 patients who received therapeutic LMWH (enoxaparin > 40 mg and/or dalteparin > 5000 IU) and/or who had diagnosis of VTE before LMWH, and 539, 175, and 200 patients who had hemorrhage in hospital were excluded from the colectomy, oophorectomy, and hysterectomy cohort. Number of patients after applying IPTW is 39,549, 10,435, and 14,479 for the colectomy, oophorectomy, and hysterectomy cohortrespectively.
171, 147, and 166 patients who received therapeutic LMWH (enoxaparin > 40 mg and/or dalteparin > 5000 IU) and/or who had diagnosis of VTE before LMWH, and 2,677, 651, and 503 patients who had any complications in hospital were excluded from the colectomy, oophorectomy, and hysterectomy cohort. Number of patients after applying IPTW is 37,407, 9,926, and 14,165 for the colectomy, oophorectomy, and hysterectomy cohortrespectively.
Number of events was weighted by the inverse probability of treatment weighting and rounded to integer.